Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HERAN2 Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC A Randomised Multicentre Phase II Feasibility Study

NCT05548504 is registered in ClinicalTrials.gov with Odense University Hospital as lead sponsor.

NCT NCT05548504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05548504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HERAN2 Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC A Randomised Multicentre Phase II Feasibility Study
Lead sponsor
Odense University Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2022
Completion date
September 30, 2029
Enrollment
182 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

frailty, non-small cell lung cancer stage iii, radiotherapy side effect